Michele Veneziani

Table S1-S3 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Table S1. Antibodies for Immunohistochemistry; Table S2. Magnitude of Sampling; Table S3. Magnitude of Sampling

Figure S1-S4 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Clinicopathological correlations. Figure S1: PD-L1 Expression and Clinicopathologic Parameters; Figure S2: PD-L1 Expression and TILs; Figure S3: TILs and Clinicopathological Parameters; Figure S4: NSCLC Immune Microenvironments Based on PD-L1 and TILs.

Data from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Abstract Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cell lung cancer (NSCLC), an extended analysis of PD-L1 and …

Data from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Abstract Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cell lung cancer (NSCLC), an extended analysis of PD-L1 and …

Table S1-S3 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Table S1. Antibodies for Immunohistochemistry; Table S2. Magnitude of Sampling; Table S3. Magnitude of Sampling

Figure S1-S4 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Clinicopathological correlations. Figure S1: PD-L1 Expression and Clinicopathologic Parameters; Figure S2: PD-L1 Expression and TILs; Figure S3: TILs and Clinicopathological Parameters; Figure S4: NSCLC Immune Microenvironments Based on PD-L1 and TILs.

MA03.03 CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC

Filippo Gustavo Dall’Olio, Francesca Abbati, Francesco Facchinetti, Francesco Gelsomino et autres

it (code pays fourni par la source)

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Giulia Mazzaschi, Francesco Facchinetti, Gabriele Missale, Diana Canetti et autres

it (code pays fourni par la source)

Clinical and Hematologic Parameters Address the Outcomes of Non-Small-Cell Lung Cancer Patients Treated With Nivolumab

Francesco Facchinetti, Michele Veneziani, Sebastiano Buti, Francesco Gelsomino et autres

AIM: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab. MATERIALS & METHODS: Correlations of several parameters with disease control and survival outcomes were provided. RESULTS: A …

it (code pays fourni par la source)

Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC

Giulia Mazzaschi, Denise Madeddu, Michele Veneziani, Francesco Sogni et autres

it (code pays fourni par la source)

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Abstract Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cell lung cancer (NSCLC), an extended analysis of PD-L1 and …

it (code pays fourni par la source)

Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab

Marcello Tiseo, Fabio Facchinetti, Sebastiano Buti, Francesco Gelsomino et autres

it (code pays fourni par la source)